Methyluracil

Instruction manual

For medical use of the drug

Methyluracil-pharmex

(methyluracil-pharmex)

Structure:

Active substance: methyluracilum;

1 suppository contains methyluracil - 500 mg;

excipient: solid fat.

Dosage form.

Rectal suppositories.

Basic physical and chemical properties: smooth suppositories of white or almost white color with a uniform consistency. The presence of a funnel-shaped recess and an air rod are allowed.

Pharmacotherapeutic group.

Non-steroidal anabolic agent. code akh a14v.

Pharmacological properties.

Pharmacodynamics

The drug has anabolic and anti-catabolic properties. It accelerates the regeneration processes, wound healing, stimulates cellular and humoral immunity, has an anti-inflammatory effect. A specific property of the drug is a stimulating effect on erythro- and especially on leukopoiesis.

Pharmacokinetics

With the introduction of a suppository into the rectum, the drug is well and almost completely absorbed through the mucous membrane and appears in the blood after 20-30 minutes. The maximum concentration in the blood is reached after 1-2 hours. It is excreted mainly by the kidneys in the form of metabolites and conjugates and partially with feces unchanged.

Clinical characteristics.

Indications.

Methyluracil is used in inflammatory and ulcerative processes of the lower parts of the large intestine (erosive-ulcerative colitis, proctitis, sigmoiditis, anal fissures).

Contraindications

Individual hypersensitivity to the components of the drug. in acute and chronic leukemic forms of leukemia (especially myeloid), lymphagranulomatosis, malignant bone marrow diseases.

Interaction with other drugs and other types of interactions.

Methyluracil enhances the effect of strophanthin, increases the effect of antibiotics and sulfa drugs.

Features of the application.

The drug should be prescribed for mild forms of leukopenia. in case of moderate disease, the drug should be taken only after the resumption of impaired blood cell regeneration. in severe forms of hematopoiesis, do not prescribe methyluracil.

Use during pregnancy or lactation.

The drug should not be used during pregnancy and / or breastfeeding.

The ability to influence the reaction rate when driving vehicles or other mechanisms.

Until the patients individual reaction to the drug is clarified, one should refrain from driving vehicles or working with other mechanisms, given that during the treatment with methyluracil, adverse reactions from the nervous system such as dizziness are possible.

Dosage and administration.

Before use, the suppository should be removed from the blister.

The drug is intended for rectal use. Adults and children over 14 years: 1 suppository 1–4 times a day. The course of treatment is from 7 days to 4 months, depending on the nature of the disease.

Children.

The drug should not be used to treat children under 14 years of age.

Overdose.

Overdose and toxic effects when using the drug have not been identified.

Adverse Reactions

From the nervous system: headache, dizziness.

On the part of the skin and subcutaneous tissue: allergic reactions, including hyperemia, itching, skin rashes, urticaria.

Changes in the injection site: when the suppository is introduced into the rectum, a short burning sensation, itching is sometimes felt.

Shelf life.

3 years.

Storage conditions.

Store in the original packaging at a temperature not exceeding 25 °С.

Keep out of the reach of children.

Packaging.

5 suppositories in a strip, 2 strips in a pack of cardboard.

Vacation category.

Over the counter.

Manufacturer.

LLC “farmex group”.

The location of the manufacturer and his address of the place of business.

Ukraine, 08301, Kiev region, g.Borispol, st. Shevchenko, building 100.

All cases of adverse reactions must be reported to the manufacturer:

Farmeks Group LLC, Ukraine, 08301, Kiev region, Boryspil, st. Shevchenko, building 100, tel .: +38 (044) 391–19–19, fax: +38 (044) 391–19–18 or through the form on the website: http://www.pharmex.com.ua/farmakonadzor